How to buy Medtronic (MDT) shares in Australia

Medtronic PLC (MDT) is a leading medical devices business with stocks listed in the US. It closed the previous market day at US$80.03. During the previous open market day, the price has varied from a low of USD80 to a high of USD81.66. Medtronic is listed on the NYSE. All prices are listed in US Dollars.

Have Medtronic's shares ever split?

Medtronic's shares were split on a 2:1 basis on 26 September 1999. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.

Medtronic shares at a glance

52-week range	US$75.3656 - US$92.68
50-day moving average more info button	US$87.4464
200-day moving average more info button	US$84.4362
Target price	US$96.1126
PE ratio more info button	24.474
Dividend yield more info button	US$0 (3.2%)
Earnings per share (TTM) more info button	US$3.27

Medtronic share growth calculator

Investment amount

US$

Investment period Choose a point in time from the list 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago 2 years ago 3 years ago 5 years ago

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Medtronic price performance over time

Historical closes compared with the last close of $80.03

Compare trading platforms to buy Medtronic shares

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Medtronic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Medtronic under- or over-valued?

Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Medtronic's P/E ratio

Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Medtronic shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Medtronic's PEG ratio

Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4856. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Medtronic's EBITDA

Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$9 billion (£7.1 billion).

The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure stock profitability.

Medtronic share price volatility

Over the last 12 months, Medtronic's shares have ranged in value from as little as US$75.3656 up to US$92.68. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.853. This would suggest that Medtronic's shares are less volatile than average (for this exchange).

Medtronic financials

Revenue TTM	US$32.6 billion
Operating margin TTM	17.51%
Gross profit TTM	US$21.7 billion
Return on assets TTM	4.42%
Return on equity TTM	7.95%
Profit margin	12.06%
Book value	38.292
Market capitalisation more info button	US$102.6 billion
EBITDA more info button	US$9 billion

TTM: trailing 12 months

Medtronic share dividends

Dividend payout ratio: 53.14% of net profits

Recently Medtronic has paid out, on average, around 53.14% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.2% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 3.2% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $0 per share.

Medtronic's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Medtronic's most recent dividend payout was on 9 January 2025. The latest dividend was paid out to all shareholders who bought their shares by 26 September 2024 (the "ex-dividend date").

Medtronic's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Medtronic's total ESG risk score

Total ESG risk: 26.86

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 12/31/2018) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Medtronic's environmental score

Environmental score: 4.07/100

Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Medtronic's social score

Social score: 15.28/100

Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Medtronic's governance score

Governance score: 9/100

Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Medtronic's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Medtronic PLC was last rated for ESG on: 2019-01-01.

Total ESG score	26.86
Total ESG percentile	40.62
Environmental score	4.07
Environmental score percentile	5
Social score	15.28
Social score percentile	5
Governance score	9
Governance score percentile	5
Level of controversy	3

Medtronic overview

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

Frequently asked questions

• What percentage of Medtronic is owned by insiders or institutions?

  Currently 0.258% of Medtronic shares are held by insiders and 85.42% by institutions.

• When does the fiscal year end for Medtronic?

  Medtronic's fiscal year ends in April.

• Where is Medtronic based?

  Medtronic's address is: Building Two, Galway, Ireland

• What is Medtronic's ISIN number?

  Medtronic's international securities identification number is: IE00BTN1Y115

• What is Medtronic's CUSIP number?

  Medtronic's Committee on Uniform Securities Identification Procedures number is: 585055106